Should-Cost Modeling And Clean-Sheet Costing

The following discussion illustrates a project that is well suited to the capabilities of an independent consultant in the Umbrex Biotechnology Practice. This is an illustrative example. Umbrex consultants adapt their methodology, timeline, and deliverables to the specific needs of each client.

1) Client Situation

The client operated within the therapeutics-focused biotech ecosystem and required support with Should-Cost Modeling And Clean-Sheet Costing in the context of Biotechnology. Teams across Emerging Therapeutic Biotech (Preclinical), Clinical-Stage Biotech (Phase I–III), Commercial Biotech (Post-Approval), Platform Biotech (Therapeutic Discovery), and Biotech Investors & Incubators sought fact-based pricing and total cost transparency for single-use assemblies (SUAs), chromatography resins, media and buffers, primary packaging (vials/stoppers/seals), and contract services (CDMO/CRO). The current-state diagnostic highlighted pain points that limited negotiating leverage and obscured the link between category strategy and COGS performance:

• Limited price transparency and weak negotiation anchors. Pricing for resins, filters, films, elastomers, gamma irradiation, vial glass, and sterilization was presented as bundled list discounts without line-of-sight to drivers, yields, or lifetime assumptions. CDMO/CRO rate cards and pass-through policies were not standardized, and change orders accumulated without clear productivity benchmarks.
• Specification proliferation and non-value-adding variety. Functionally equivalent SUAs, filter grades, and container closure combinations were purchased across sites/CDMOs, increasing qualification burden, minimum order quantity (MOQ) exposure, and obsolescence risk, while diluting volume leverage.
• Supplier-driven indexation and surcharges. Energy, logistics, and raw-material surcharges were introduced piecemeal. Indexation formulas were vendor-authored, unbalanced, or uncapped, with limited linkage to relevant indices (e.g., natural gas, soda ash, solvents, precious metals for ligands, ethylene/isoprene for elastomers).
• Unmodeled lifetime and yield assumptions. Protein A and ion-exchange resin lifetimes, filter changeout criteria, vial forming yields, stopper coating scrap, and gamma dose derates for SU films were assumed rather than measured. Negotiations lacked credible counterfactuals to challenge price-per-cycle or per-validated-dose economics.
• Fragmented TCO and landed-cost view. Duties/tariffs (HS codes), brokerage, lane-specific freight, cold-chain accessorials, irradiation, sterilization/depyrogenation, and documentation costs (CoA/CoC, E&L) were not captured consistently. Total landed cost (TLC) differences across vendors and lanes were invisible in award decisions.
• Service cost opacity for CDMOs/CROs. Utilization assumptions, staffing pyramids, productivity norms (e.g., EDC build hours, SDTM/ADaM deliverable effort, PPQ batch documentation hours), and overhead absorption were not benchmarked. Rate ladders and markup caps on pass-throughs were not enforced.
• Data and system limitations. Item masters lacked cost-driver attributes (resin ligand type, base matrix, film thickness, elastomer formulation, glass forming line), while P2P data contained inconsistent UoM and pack sizes. Cost data lived in spreadsheets, constraining traceability and auditability.
• Governance gaps. Savings baselines, purchase price variance (PPV) definitions, and COGS bridges were not standardized. There was no formal target-price setting or agreement on indexation caps/floors, and approvals for deviations were inconsistent across business units and CDMOs.
• Supplier concentration and resilience risks. Single-source dependencies existed for SU films, specific resin chemistries, sterilizing-grade filters, and Type I borosilicate vials. Dual-sourcing thresholds and alternates qualification timelines were not embedded in category strategies.

Observed KPIs reflected these issues: PPV above tolerance, inconsistent indexation impacts, higher-than-planned pass-throughs, frequent CDMO/CRO change orders, inventory write-offs in SUAs and packaging, and unstable COGS due to unmodeled freight, duty, and energy surcharges. Negotiation cycles extended without decisive anchors to drive toward target prices.

2) Project Objective

The primary objective focused on developing should-cost and clean-sheet costing models for single-use assemblies, chromatography resins, media and buffers, vials/stoppers/seals, and contract services (CDMO/CRO), and embedding those models into sourcing, negotiations, and governance to set target prices, inform award decisions, and strengthen resilience without compromising compliance or performance.

Secondary objectives included:

• Standardizing cost-driver taxonomies and model structures across categories, with version control and audit trails suitable for procurement, finance, QA/Regulatory, and technical teams.
• Capturing total landed cost (TLC) and service total cost of ownership (TCO), including duties/tariffs, logistics, irradiation/sterilization, documentation, and change-order governance.
• Defining indexation formulas and bands tied to verifiable indices and FX policies, with caps/floors and review cadences.
• Quantifying lifetime and yield assumptions (e.g., Protein A cycles, filter area utilization, CCIT-related pack loss) to support price-per-cycle negotiations and value engineering.
• Integrating should-cost targets into RFx scoring, award optimization, and LTA/QTA contracting constructs (price protection, markup caps, pass-through controls).
• Standing up dashboards and operating rhythms to track PPV, COGS bridges, indexation impacts, and realized economics versus targets.
• Building capability through playbooks and training for category managers and cross-functional stakeholders to sustain fact-based negotiations.

3) Methodology and Approach

Workstream 1: Category Scoping, Spend Cube, and Cost-Driver Baseline

We constructed a common fact base and mapped key cost drivers for each in-scope category, partnering with Procurement, Finance, MSAT, QA/Regulatory, Packaging Engineering, Tech Ops, and External Manufacturing.

• Consolidated 24–36 months of PO, invoice, and receipt data by item/vendor/site/CDMO; reconciled UoM/pack sizes; built a spend cube segmented by category and subcategory (e.g., Protein A vs. ion-exchange resins; films/tubing/connectors vs. sterile manifolds; vial forming vs. washing/sterilization).
• Gathered specifications and process dependencies: resin chemistries, base matrix, coupling method; SU film type and thickness, gamma dose rating; tubing ID/OD; connector types; filter membrane area and pore ratings; vial glass type and forming line; stopper elastomer and coatings; seal materials; E&L requirements and Annex 1/CCIT considerations.
• Profiled vendor pricing constructs and surcharges: indexation clauses, energy/freight adders, duty/tariff exposure by HS code; sterilization/irradiation fees; documentation costs (CoA/CoC/E&L updates); QA lot-release fees.
• Mapped CDMO/CRO service rate cards and pass-throughs: labor pyramids, utilization assumptions, overhead/SG&A rates, typical hours per deliverable (e.g., EDC build, PV case processing, batch record authoring), and change-order triggers.

This baseline clarified cost/price dispersion, revealed specification proliferation and unleveraged volumes, and identified where TLC/TCO components dominated award outcomes.

Workstream 2: Technical Teardowns and Clean-Sheet Costing for SUAs and Packaging

We built bottom-up clean sheets for single-use assemblies and primary packaging, integrating materials, conversion, quality, and logistics, with cross-functional validation.

• Single-use assemblies:
  • Itemized raw materials: films (polyethylene, EVA, fluoropolymers), tubing (silicone, TPE), connectors (polycarbonate, PEEK, stainless), filters (membrane, housings), gaskets, clamps.
  • Modeled fabrication and conversion: extrusion, molding, welding, overmolding, assembly labor content by takt; cleanroom classifications; in-process yields; quality inspection protocols; gamma irradiation cost per kg and per shipment; validation/documentation labor.
  • Allocated overhead and SG&A: facility costs, depreciation, sterilization logistics, packaging materials, warehousing, compliance/QA batch release, serialization/labeling where required.
  • Embedded logistics and duties: lane-specific freight, accessorials, customs/brokerage, duties by HS code; temperature or irradiation transit requirements.
• Primary packaging (vials/stoppers/seals):
  • Vials: silica batch and forming yields, Type I borosilicate vs. aluminosilicate costs, forming line speed, annealing losses, cosmetic inspection and reject rates, washing and depyrogenation, sterilization fees.
  • Stoppers: elastomer compounds (butyl/isoprene), fluoropolymer coatings (e.g., FEP/ETFE), molding and curing cycles, washing/sterilization, particle specifications, E&L test packages, CCIT dependencies.
  • Seals: aluminum or stainless compositions, anodization/coating options, forming and slitting; color standards; loaded QC requirements.
  • Packs and kitting: trays, nests, sterile vs. non-sterile configurations; secondary packaging and labeling costs; palletization efficiency.
• Produced parametric clean sheets that adjusted for volume, pack size, sterilization method, and regional lane differences; validated against supplier disclosures and third-party benchmarks.

The teardowns yielded defensible target prices at the component and assembly levels and clarified where design or qualification choices drove cost.

Workstream 3: Process-Based Should-Cost for Resins, Media, and Filters

We modeled unit economics for chromatography resins, media/buffers, and sterilizing-grade filters using process physics, lifetime assumptions, and lab/plant data.

• Protein A and ion-exchange resins:
  • Ligand synthesis and coupling yields (precious metal catalysts or specialty reagents), base matrix cost (agarose/other), work-up and QC costs, column packing and qualification.
  • Lifetime and productivity: cycles to failure, clean-in-place regimes, pressure-flow limits, resin carryover losses, performance mapping across batch sizes; calculated cost per cycle and cost per gram of product using expected DBC and step yields.
  • Regulatory and documentation: lot release testing, CofA package, shelf-life, storage and handling costs.
• Media and buffers:
  • Chemically defined media constituents (amino acids, vitamins, trace metals), controlled-substance/animal-origin exclusions, mixing/solubilization times, filtration and sterile handling, powder vs. liquid packs.
  • Supplier conversion and QC: blending equipment, sieving, moisture control; sterility assurance steps; documentation of CoA and adventitious agent testing; pack line speeds and yields.
  • Logistics: pack density, pallet cube, lane costs; duties and import controls for specific precursors.
• Sterilizing-grade filters:
  • Membrane type, area, housing costs, integrity testing; gamma or steam compatibility; batch-level QC and lot release.
  • Changeout criteria and area utilization; step cost per liter filtered under typical TMP and foulant profiles.
• Developed price-per-cycle or per-liter targets anchored in physics and validated by MSAT and batch records; incorporated sensitivity to lifetime, yield drift, and fouling patterns.

Process-based models provided clear levers—lifetime extension, area optimization, batch-size alignment—to underpin VAVE and negotiating positions.

Workstream 4: Service TCO Models for CDMO/CRO

We constructed activity-based service cost models for CDMOs and CROs to benchmark rate cards, productivity, and pass-through governance.

• CDMOs:
  • Resource pyramids and utilization: role ladders, billable vs. non-billable hours, expected utilization, shift patterns for DS/DP/sterile suites.
  • Facility and equipment: cleanroom occupancy costs, equipment depreciation and maintenance, utilities (CIP/SIP, WFI/clean steam), quality batch record authoring and QA review hours.
  • Milestone-based costing: tech transfer, method transfer/validation, engineering runs, PPQ batches; documentation and regulatory support hours.
  • Pass-through governance: raw materials, SU kits, testing, freight/duties; markup caps and pre-approval thresholds.
• CROs:
  • Study start-up: feasibility, site identification/activation, contracts and budgets, regulatory submissions; expected cycle times and hours per site.
  • Data management/biostats: EDC build/config/validation hours by complexity, mid-study changes, query rates, SDTM/ADaM deliverable hours, programming QC norms.
  • Safety/PV: case processing and medical review hours by case complexity; signal detection cycles; compliance reporting.
  • eTMF operations and QC staffing ratios; database lock predictability metrics; country/regional variations.
• Benchmarked against historicals and third-party data; derived fact-based rate ladders, productivity norms, and change-order guardrails.

Service TCO models created transparent targets for rate cards, utilization assumptions, and pass-through caps, improving predictability and negotiating posture.

Workstream 5: Indexation, FX, and Market Intelligence

We defined balanced indexation formulas, FX treatments, and competitive context to stabilize pricing over time.

• Selected relevant indices by category: natural gas/electricity (sterilization/energy), soda ash and silica (glass), precious metals/solvents (ligands), ethylene/isoprene (elastomers), logistics (air/sea freight benchmarks), and labor CPI for services.
• Designed indexation formulas with caps/floors and review cadence; separated structural price changes (scope, spec) from indexation adjustments; defined FX baselines and thresholds for re-pricing aligned with treasury policy.
• Compiled market capacity, lead-time norms, consolidation trends, and regional alternatives; identified dual-source candidates and parametric gaps for negotiation.

Indexation and market intelligence anchored multi-year constructs and reduced exposure to unilateral surcharge practices.

Workstream 6: Total Landed Cost and Award Optimization

We built TLC calculators and RFx scoring that reflected end-to-end economics and resilience, rather than unit price alone.

• Modeled TLC components: duties/tariffs by HS code, brokerage, lane freight and accessorials, irradiation/sterilization, QA lot-release/documentation, E&L updates, CCIT impacts, pack density and pallet cube, spoilage risk by lane.
• Encoded resilience metrics: dual-source coverage, supplier BC/DR posture, allocation priority, lead-time variability, and alternates qualification timelines.
• Integrated TLC and resilience into RFx scoring and award optimization scenarios; produced executive-ready trade-offs between price, TLC, and risk.

TLC-based award decisions improved COGS predictability and protected schedules by valuing service and risk constructs explicitly.

Workstream 7: Target-Price Setting, Negotiation Playbooks, and RFx Integration

We operationalized the models with target-setting, playbooks, and RFx tools that guided negotiations and contracting.

• Set target prices and bands per item/service with clear variance thresholds; defined walk-away points and fallback positions (e.g., indexation caps, longer commitments for value).
• Authored negotiation playbooks per category: concession sequences, fact-base exhibits (clean-sheet components, lifetime/yield analyses), and alternative scenarios (dual-source splits, design-for-cost options).
• Embedded models into e-sourcing templates, scoring, and award optimization; prepared term-sheet clauses for indexation, pass-through caps, VMI/consignment, and price protection.

Playbooks translated analytical insights into consistent, disciplined negotiation behavior and contracting constructs.

Workstream 8: Governance, Training, and Analytics Deployment

We implemented governance and tools to sustain the cost discipline and ensure traceability for audits and executive reviews.

• Established category councils and approval thresholds for deviations from target prices; standardized PPV and savings recognition rules; linked to S&OP/IBP cadences.
• Delivered training for category managers, MSAT, QA, and Finance on model use, indexation reviews, and RFx integration; created quick-reference guides and model primers.
• Deployed dashboards showing PPV, COGS bridges, indexation impacts, TLC by lane/vendor, and realized economics vs. targets; instituted quarterly model refreshes and market reviews.

Governance and analytics provided routine visibility and reinforced accountability across functions and partners.

4) Data Request

We requested the following datasets to execute Should-Cost Modeling And Clean-Sheet Costing for clients across Emerging Therapeutic Biotech, Clinical-Stage Biotech, Commercial Biotech, Platform Biotech, and Biotech Investors & Incubators. Typical horizons and granularity were specified, along with common pitfalls to be addressed upfront.

• Procurement/spend and operational demand (24–36 months; monthly granularity):
  • PO lines, invoice details, receipts by item/vendor/site/CDMO; UoM, pack sizes, Incoterms, lead times, price breaks, surcharges (energy, freight).
  • BOM consumption factors by batch and scale; campaign calendars; tech transfer/PPQ plans; CDMO pull signals for SUAs and packaging.
• Technical specifications and quality:
  • Resin specifications (ligand, base matrix, coupling method), lifetime/cycle data, CIP recipes, DBC profiles; filter specifications and area; SUA drawings and bills of labor; gamma dose specs and certificates; films/tubing/connectors materials.
  • Media/buffer formulations (if available) or constituent groups; sterile vs. non-sterile pack formats; lot-release and CoA parameters.
  • Primary packaging specs: vial glass type and forming line; stopper elastomer and coatings; seals; washing/sterilization/depyrogenation steps; CCIT dependencies; E&L packages.
  • QA/Regulatory requirements impacting cost (Annex 1, CCIT standards, E&L scope, documentation requirements).
• Logistics and landed cost:
  • Freight rates by lane/mode; accessorials; irradiation/sterilization costs; brokerage and customs data; HS codes and duty rates by item; pallet cube and pack density.
  • Warehouse handling, temperature controls (if applicable), and inventory holding cost assumptions.
• Supplier economics and market:
  • Indexation clauses; prior index adjustments; FX exposure details; energy surcharges; vendor disclosure on capacity/lead-time norms.
  • Market intelligence on capacity consolidation, lead-time trends, regional alternates.
• Service rate cards and productivity (CDMO/CRO):
  • Role ladders with hourly rates; utilization assumptions; markups on pass-throughs; overhead/SG&A rates; standard milestone pricing where applicable.
  • Hours per deliverable for EDC build, site start-up, PV case processing, SDTM/ADaM packages; batch record authoring and QA review hours for CDMOs; change-order histories and rationales.
• Finance and governance:
  • COGS bridges, standard vs. actual variances; PPV rules; indexation/FX policy; working capital targets and inventory turns.
  • Existing LTAs/QTAs; price protection clauses; pass-through caps; savings recognition methods.
• Systems and data architecture:
  • ERP item/vendor masters with cost-driver attributes; P2P workflow and approval matrices; e-sourcing templates; data governance policies; report exports.

Common data quality pitfalls included inconsistent UoM and pack sizes across records; missing cost-driver attributes (material, film thickness, resin type); free-text specifications; incomplete duty/HS code mappings; custom surcharges not codified; and fragmented change-order data for services. We instituted data dictionaries, normalization and reconciliation routines, and change logs prior to modeling and negotiations.

5) Questions for Client

• Which categories and services are in scope for the initial wave, and what decision timeline must negotiations support (e.g., PPQ/launch, pivotal starts)?
• What specification boundaries are non-negotiable for MSAT/QA, and where can functional equivalence or design-for-cost be considered without compromising compliance?
• How should we prioritize resilience versus price (dual-source coverage, indexation bands, VMI/consignment), and what risk thresholds apply?
• What indexation and FX policy should govern multi-year constructs (indices, caps/floors, review cadence, currency thresholds)?
• What pass-through and markup caps are acceptable for materials, testing, freight, and third-party services, and what pre-approval thresholds should apply?
• What walk-away and fallback positions are acceptable (longer commitment for price protection, tiered volume rebates, alternates sequencing)?
• How will savings and PPV be recognized (baselines, counterfactuals, timing), and what reporting cadence will support board or investor communications?
• Which suppliers are strategic or restricted due to IP, quality, or geographic concerns, and where is dual-sourcing mandatory?
• What TLC components must be embedded in award decisions (duties, irradiation, QA documentation costs), and how should we weight resilience metrics?
• What change-control timelines and QTA/QSA clauses must be reflected in contracts to avoid delays in activation?
• Which CDMOs/CROs require near-term renegotiation or harmonization of terms, and what lessons from prior contracts should shape our negotiation stance?
• What governance and approval thresholds should apply to deviations from target prices or indexation bands?
• What confidentiality constraints or antitrust considerations limit benchmarking and model disclosure to suppliers?
• What training or tooling is needed for the team to adopt clean-sheet models in live negotiations?

6) Interview Guide for Subject Matter Experts

Head of Procurement / Category Leads

• Where is price dispersion highest within SUAs, resins, packaging, and services, and what vendor narratives drive it?
• Which surcharges and indexation claims have been most challenging to assess, and how have we responded historically?
• Where have RFx or e-auctions delivered strong outcomes, and what design features (lotting, alternates) were critical?
• What are typical barriers to consolidating volumes across sites/CDMOs, and where can governance unlock leverage?
• Which contracts include strong price protection, pass-through caps, or indexation bands we should replicate?

MSAT / Process Development

• Which resin and filter performance parameters define functional equivalence, and what variability can processes tolerate?
• How do resin lifetime and filter changeout criteria vary by program, and what data supports target cycles?
• Where have SU design choices (film type, tubing ID, connector formats) driven yield or contamination risk, and what standardization is feasible?
• What VAVE opportunities (resin lifetime extensions, filter area optimization, manifold simplification) can be realized without revalidation burdens?
• How should we quantify and negotiate productivity levers with CDMOs (batch documentation hours, method transfer effort)?

QA / Regulatory

• What E&L, CCIT, Annex 1, and documentation requirements most impact cost and lead time, and where can we harmonize?
• Which QTA/QSA clauses must be embedded in pricing constructs (change control timelines, audit rights, data integrity, sample retention)?
• Where do vendor documentation gaps (CoA completeness, audit trail access) create rework or inspection exposure?
• How should we validate indexation formulas and price-protection mechanisms within quality and compliance constraints?
• What evidence is needed to accept alternates or dual-sourcing from a quality perspective?

Packaging Engineering / Tech Ops

• Which vial/stopper/seal combinations are core, and where do equivalent alternates exist with similar E&L and CCIT performance?
• What forming yields and cosmetic defect rates should be assumed by forming line and supplier?
• How do pack formats and kitting choices impact TLC (cube, freight, labor), and where can standards reduce cost?
• What sterilization/depyrogenation and labeling constraints drive differences in supplier economics?
• Where do we see obsolescence risk in packaging SKUs, and how can we consolidate?

Finance / Cost Accounting

• How are standards set and updated; where do variances (PPV, usage, mix) arise most frequently?
• Which TLC elements (duties, freight, irradiation, QA documentation) are most material and least visible today?
• What indexation and FX policies apply; how should we measure and report impacts?
• What working-capital considerations (buffers, VMI) should shape award and contract terms?
• Which savings recognition rules and timing windows do we need for governance and board reporting?

External Manufacturing / CDMO Management

• Which SU kits and packaging are sponsor-owned vs. CDMO-procured, and how does that impact cost and lead-time control?
• Where do AML/AVL misalignments create change-control delays and cost pass-through disputes?
• How can we implement VMI/consignment and min/max policies at CDMOs to stabilize TLC and service?
• What are the most frequent drivers of change orders, and what model-based guardrails could prevent them?
• What joint KPIs reinforce productivity and predictability in cost for CDMO services?

Clinical Operations / Biometrics (for CRO services)

• What assumptions around EDC build hours, mid-study changes, and database lock predictability are realistic by protocol complexity?
• Where do site start-up cycle times most often slip, and what cost levers (bundled start-up, resourcing commitments) change outcomes?
• How should we benchmark SDTM/ADaM productivity and QC performance in SOWs?
• What pass-through controls and markup caps are most important to enforce cost predictability?
• Where have prior CRO contracts lacked protections that matter operationally?

IT / P2P / Data Governance

• Which item master attributes are missing for cost models (film specs, resin type), and how can we enforce data completeness?
• What e-sourcing and award-optimization features can embed should-cost targets and TLC scoring?
• What dashboards and automated extracts can keep models current with price and indexation changes?
• How will we maintain model version control and audit trails for procurement and finance?
• What integration constraints exist with CDMO/CRO portals for rate cards and status feeds?

7) Timeline

We executed a 12-week plan with decision gates aligned to Should-Cost Modeling And Clean-Sheet Costing within Procurement & Strategic Sourcing.

• Weeks 1–2: Mobilize and Baseline
  • Confirmed in-scope categories and services; aligned governance, savings/PPV rules, and target-setting approach.
  • Completed data intake and cleansing; built the spend cube; profiled pricing constructs, surcharges, and indexation; gathered specifications and process dependencies.
  • Decision Gate A: Approved category priorities, cost-driver taxonomy, and clean-sheet/should-cost modeling plan.
• Weeks 3–4: Technical Teardowns and Process Models
  • Developed clean sheets for SUAs and packaging; executed process-based models for resins, media, and filters; validated lifetime and yield assumptions with MSAT and QA.
  • Built service TCO frameworks for CDMO/CRO rate cards and deliverables; benchmarked productivity norms.
  • Decision Gate B: Ratified model structures and key assumptions; set preliminary target-price bands by category.
• Weeks 5–6: Indexation/TLC and RFx Integration
  • Defined indexation formulas, caps/floors, and FX thresholds; constructed TLC calculators; encoded resilience metrics for award optimization.
  • Embedded targets and TLC scoring into RFx templates; drafted negotiation playbooks and term-sheet clauses (indexation, pass-through caps, price protection).
  • Decision Gate C: Approved targets, TLC/award scoring, and negotiation playbooks for live events.
• Weeks 7–8: Market Engagement and Calibration
  • Ran market soundings and RFx pilots; conducted supplier clarifications and open-book sessions to calibrate assumptions; refined clean sheets as needed.
  • Modeled award scenarios with dual-source splits and resilience thresholds; prepared executive trade-off exhibits.
  • Decision Gate D: Selected finalist scenarios and negotiation stance; authorized term-sheet issuance.
• Weeks 9–10: Negotiations and Contract Constructs
  • Executed negotiations using clean-sheet fact packs; converged on indexation bands, pass-through caps, price protection, and resilience constructs (dual-sourcing, VMI/consignment).
  • Aligned on QTA/QSA clauses impacting cost (change controls, documentation fees); harmonized with LTA/MSA term sheets.
  • Decision Gate E: Reconciled commercial and quality/legal terms; approved final terms for contract drafting.
• Weeks 11–12: Implementation and Governance
  • Updated ERP item/vendor masters, catalogs, and P2P workflows; launched dashboards for PPV, COGS bridges, indexation impacts, TLC metrics.
  • Stood up category councils; finalized training on models/playbooks; scheduled quarterly model refreshes and market reviews.
  • Decision Gate F: Activated steady-state governance; defined 90–180 day roadmap for additional categories and continuous improvement.

Critical path items included timely access to specifications and lifetime/yield data; alignment on indexation and FX policy; supplier openness for calibration; coordination with QA/Regulatory on documentation cost implications; and P2P master-data updates to avoid mispricing and change-order errors.

8) Deliverables

• Clean-Sheet and Should-Cost Model Library
  • Parametric models for SUAs, resins, media, filters, and packaging; service TCO models for CDMO/CRO; version-controlled with assumption logs and data sources.
• Indexation and FX Policy Pack
  • Balanced index formulas by category with caps/floors, review cadence, and FX thresholds; examples of application to current suppliers.
• Total Landed Cost and Award Optimization Toolkit
  • TLC calculators by lane/vendor with duties, brokerage, irradiation/sterilization, QA documentation, pack density; award optimization templates incorporating resilience metrics.
• Target-Price Benchmarks and Negotiation Playbooks
  • Target bands by item/service; fact packs (lifetime/yield analyses, clean-sheet components); concession sequences and fallback positions; supplier-specific exhibits.
• RFx and Term-Sheet Templates
  • e-sourcing RFx templates with embedded targets and TLC scoring; term-sheet clauses for indexation, pass-through caps, price protection, VMI/consignment, and dual-source splits.
• Contracting Constructs and QTA/QSA Alignment Guide
  • Model-linked contracting language for LTAs/MSAs; alignment checklist for QTA/QSA clauses affecting cost and activation timelines.
• Governance Charter and KPI Dashboard
  • Category council charters, approval thresholds, PPV and COGS bridge definitions; dashboards for realized economics vs. targets, indexation impacts, TLC metrics, and resilience coverage.
• Training and Adoption Materials
  • Model primers, quick-reference guides, RFx scoring guides, and playbook training for category managers and cross-functional partners.
• Executive Decision Memos
  • Scenario trade-offs (price vs. TLC vs. resilience), supplier calibration outcomes, target-price justification, and recommended awards or renegotiation strategies.
• Continuous Improvement Roadmap
  • 90–180 day plan for model refreshes, additional categories, VAVE initiatives (resin lifetime extensions, filter area optimization, packaging consolidation), and indexation reviews.

9) Industry Insights

Industry dynamics influenced Should-Cost Modeling And Clean-Sheet Costing in Biotechnology and Procurement & Strategic Sourcing and shaped how category strategies were executed.

• Supplier consolidation and capacity:
  • SU and filtration markets exhibited consolidation and periodic capacity constraints, increasing the need for AML/AVL discipline, dual-sourcing, and sterilization slot assurance. Competitive tension depended on well-qualified alternates and design-for-cost options.
  • Protein A resin pricing reflected ligand synthesis complexity, yields, and global demand; lifetime extension and column utilization were often the most material levers for economics.
• Regulatory and quality expectations:
  • Annex 1 elevated sterility assurance (CCIT) and documentation demands for packaging, impacting pack configuration economics and qualification lead times.
  • E&L rigor and data packages remained decisive in supplier selection and alternates approval; early alignment on test scope and documentation reduced cost uncertainty.
• Cost volatility and indexation:
  • Energy and freight volatility required structured indexation with caps/floors and periodic reviews. Balanced formulas anchored in verifiable indices mitigated vendor-driven surcharges and stabilized COGS trajectories.
  • FX swings impacted both materials and services; predefined thresholds for re-pricing and currency hedging policy alignment improved predictability.
• Total landed cost and logistics:
  • Duties/tariffs, brokerage, irradiation/sterilization, and QA documentation costs were frequently underweighted in awards. TLC discipline and HS code governance prevented hidden TCO creep.
  • Lane-specific risks (seasonality, hub congestion) affected spoilage and schedule assurance; TLC models that embedded resilience and lane performance outperformed unit-price-only decisions.
• Service productivity and pass-through governance:
  • CDMO/CRO rate cards without utilization and productivity anchors led to change-order creep. Activity-based models and markup caps, combined with milestone pricing where feasible, improved cost predictability.
  • Resourcing commitments, clear assumptions for EDC builds and mid-study changes, and database lock predictability metrics were differentiators for CROs.
• Design-for-cost and VAVE:
  • Resin lifetime improvements, filter area optimization, manifold simplification, and packaging consolidation delivered structural advantages when co-developed with MSAT and QA to avoid revalidation shocks.
  • Postponement strategies in packaging and standardized SU kits reduced obsolescence and improved TLC by enabling cross-program use.
• Data and tooling:
  • Clean, attribute-rich item masters and e-sourcing platforms with award optimization enabled model-informed awards and contracting; PPV and COGS bridge dashboards closed the loop in executive reviews.
  • Quarterly model refreshes linked to indexation reviews and market scans sustained credibility and negotiation readiness.
• What “good” looks like:
  • Parametric, version-controlled should-cost and clean-sheet models across categories and services; TLC and resilience embedded in RFx scoring and awards.
  • Balanced indexation and FX policies with caps/floors and review cadences; transparent pass-through caps and price protection in LTAs.
  • AML/AVL standards and dual-sourcing thresholds, with pre-approved equivalency and change-control protocols to accelerate alternates.
  • Negotiation playbooks that translate models into concession sequences and term-sheet constructs; governance that enforces target-setting and deviations approvals.
  • Dashboards that connect PPV, COGS bridges, indexation impacts, and TLC outcomes to board-ready narratives.
• Near-term disruptions and watch points:
  • Energy pricing, freight capacity, and glass/elastomer inputs remained volatile; indexation discipline and alternates qualification protected economics.
  • Evolving PFAS and materials regulations could impact elastomer and coating choices; early design and supplier disclosure mitigated surprises.
  • Continued consolidation among service providers underscored the importance of dual-source strategies, step-in rights, and balanced multi-year terms.

Implications for clients we served included enabling Emerging Therapeutic Biotech to establish early cost discipline and AML/AVL foundations; supporting Clinical-Stage Biotech with model-based targets for PPQ and pivotal ramps; equipping Commercial Biotech to stabilize COGS and TLC through indexation policy and dual-sourcing; guiding Platform Biotech to scale clean-sheet practices across programs and partners; and providing Biotech Investors & Incubators with a standardized approach to diligence cost credibility and resilience across portfolio companies.